• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

BCMA-directed CAR-T still shows deep, durable response in heavily pretreated myeloma

by | Aug 10, 2021 | Uncategorized

Source: Healio News Long-term results from the KarMMa trial continued to yield frequent deep and durable responses with idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in heavily pretreated patients with relapsed or refractory multiple myeloma.Based on...

Moving Mountains for Multiple Myeloma Program to Hike Through Alaska’s Kenai Peninsula-Glaciers, Coastline & Wildlife in August

by | Aug 9, 2021 | Uncategorized

Source: Cure Today articles Twelve hikers will embark on this incredible challenge to raise awareness and funds for multiple myeloma through the Multiple Myeloma Research Foundation. Read More

Non-invasive, inexpensive analytical tool predicts survival in multiple myeloma

by | Aug 2, 2021 | Uncategorized

Source: Healio News Post-induction of a mass spectrometry tool called Mass-Fix predicted survival outcomes among patients with multiple myeloma participating on the STAMINA trial.Mass-Fix, mass spectrometry of blood by MALDI, is an inexpensive, sensitive and specific...

Isatuximab regimen demonstrates PFS benefit in relapsed, refractory multiple myeloma

by | Aug 2, 2021 | Uncategorized

Source: Healio News Isatuximab plus pomalidomide and low-dose dexamethasone continued to show significant improvement in time to next treatment and PFS2 compared with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma, according to updated...

Elranatamab shows efficacy in relapsed, refractory multiple myeloma

by | Aug 2, 2021 | Uncategorized

Source: Healio News Subcutaneous elranatamab demonstrated efficacy and a manageable safety profile in patients with relapsed or refractory multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.Nizar J. Bahlis, MD, from the University of...

Neurologic adverse events manageable after CAR-T in multiple myeloma

by | Aug 2, 2021 | Uncategorized

Source: Healio News Neurologic adverse events were generally manageable in patients with multiple myeloma after receiving ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy, according to CARTITUDE-2 data presented at the virtual ASCO Annual...
« Older Entries
Next Entries »

Recent Content

  • A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT